Cannabinoid CB₂-Selective Inverse Agonist Protects Against Antigen-Induced Bone Loss

REFERENCES

• Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937)356–361
   PubMed Web of Science ®Google Scholar
• Abbott J.D., Moreland L.W. Rheumatoid arthritis: developing pharmacological therapies. Exp. Opin. Invest. Drugs. 2004; 13(8)1007–1018
   PubMed Web of Science ®Google Scholar
• Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 2001; 344(12)907–916
   PubMed Web of Science ®Google Scholar
• Tak P.P., Smeets T.J., Daha M.R., Kluin P.M., Meijers K.A., Brand R., Meinders A.E., Breedveld F.C. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthr. Rheum. 1997; 40(2)217–225
   PubMed Web of Science ®Google Scholar
• Schett G., Smolen J.S. New insights in the mechanism of bone loss in arthritis. Curr. Pharmaceut. Des. 2005; 11(23)3039–3049
   PubMed Web of Science ®Google Scholar
• Haringman J.J., Tak P.P. Chemokine blockade: a new era in the treatment of rheumatoid arthritis?. Arthr. Res. Ther. 2004; 6(3)93–97
   PubMed Web of Science ®Google Scholar
• Moreland L.W. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. PharmacoEcono. 2004; 22(2 Suppl)39–53
   PubMed Web of Science ®Google Scholar
• Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., Feldmann M., Maini R.N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthr. Rheumat. 2000; 43(1)38–47
   PubMed Web of Science ®Google Scholar
• Mechoulam R., Carlini E.A. Toward drugs derived from cannabis. Naturwissenschaften. 1978; 65(4)174–179
   PubMed Web of Science ®Google Scholar
• Perrot S. Cannabis: The analgesic and antiinflammatory medication of the future?. Joint Bone Spine 2004; 71(1)7–8
   PubMed Web of Science ®Google Scholar
• Goutopoulos A., Makriyannis A. From cannabis to cannabinergics: New therapeutic opportunities. Pharmacol. Ther. 2002; 95(2)103–117
   PubMed Web of Science ®Google Scholar
• Fernandez J.R., Allison D.B. Rimonabant. Curr. Opin. Invest. Drugs. 2004; 5(4)430–435
   PubMedGoogle Scholar
• Lunn C.A., Fine J., Rojas-Triana A., Jackson J.V., Schwarz M.A., Fan X., Kung T.T., Gonsiorek W., Lavey B., Kozlowski J.A., Narula S.K., Lundell D.J., Hipkin R.W., Bober L. A novel CB2-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exper. Therapeut. 2005; 316(2)780–788
   PubMed Web of Science ®Google Scholar
• Lavey B.J., Kozlowski J.A., Hipkin R.W., Gonsiorek W., Lundell D.J., Piwinski J.J., Narula S., Lunn C.A. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorgan. Med. Chem. Lett. 2005; 15(3)783–786
   PubMed Web of Science ®Google Scholar
• Shankar B.B., Lavey B.J., Zhou G., Spitler J.A., Tong L., Rizvi R., Yang D.Y., Wolin R., Kozlowski J.A., Shih N.Y., Wu J., Hipkin R.W., Gonsiorek W., Lunn C.A. Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorgan. Med. Chem. Lett. 2005; 15(20)4417–4420
   PubMed Web of Science ®Google Scholar
• Idris A.I., van't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., Ralston S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 2005; 11(7)774–779
   PubMed Web of Science ®Google Scholar
• Karsak M., Cohen-Solal M., Freudenberg J., Ostertag A., Morieux C., Kornak U., Essig J., Erxlebe E., Bab I., Kubisch C., De Vernejoul M.C., Zimmer A. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Human Mol. Gen. 2005; 14(22)3389–3396
   PubMed Web of Science ®Google Scholar
• Fine J.S., Jackson J.V., Rojas-Triana A., Bober L.A. Evaluation of chemokine- and phlogistin-mediated leukocyte chemotaxis using an in vivo sponge model. Inflammation. 2000; 24(4)331–346
   PubMed Web of Science ®Google Scholar
• Fine J.S., Rojas-Triana A., Jackson J.V., Engstrom L.W., Deno G.S., Lundell D.J., Bober L.A. Impairment of leukocyte trafficking in a murine pleuritis model by IL-4 and IL-10. Inflammation. 2003; 27(4)161–174
   PubMed Web of Science ®Google Scholar
• Buchner E., Brauer R., Schmidt C., Emmrich F., Kinne R.W. Induction of flare-up reactions in rat antigen-induced arthritis. J. Autoimm. 1995; 8(1)61–74
   PubMed Web of Science ®Google Scholar
• Penido C., Vieira-de-Abreu A., Bozza M.T., Castro-Faria-Neto H.C., Bozza P.T. ole of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma delta T lymphocyte trafficking during inflammation induced by lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guerin. J. Immunol. 2003; 171(12)6788–6794
   PubMed Web of Science ®Google Scholar
• Silva A.R., Larangeira A.P., Pacheco P., Calixto J.B., Henriques M.G., Bozza P.T., Castro-Faria-Neto H.C. Bradykinin down-regulates LPS-induced eosinophil accumulation in the pleural cavity of mice through type 2-kinin receptor activation: a role for prostaglandins. Br. J. Pharmacol. 1999; 127(2)569–575
   PubMed Web of Science ®Google Scholar
• Black C.A. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol. Online J. 1999; 5(1)7
   PubMedGoogle Scholar
• Kraan M.C., Haringman J.J., Weedon H., Barg E.C., Smith M.D., Ahern M.J., Smeets T.J.M., Breedveld F.C., Tak P.P. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63(5)483–488
   PubMed Web of Science ®Google Scholar
• Haringman J.J., Gerlag D.M., Zwinderman A.H., Smeets T.J., Kraan M.C., Baeten D., McInnes I.B., Bresnihan B., Tak P.P. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2005; 64(6)834–838
   PubMed Web of Science ®Google Scholar
• Berckmans R.J., Nieuwland R., Kraan M.C., Schaap M.C., Pots D., Smeets T.J., Sturk A., Tak P.P. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthr. Res. Ther. 2005; 7(3)R536–R544
   PubMed Web of Science ®Google Scholar
• Bukhari M.A., Wiles N.J., Lunt M., Harrison B.J., Scott D.G., Symmons D.P., Silman A.J. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthr. Rheumat. 2003; 48(1)46–53
   PubMed Web of Science ®Google Scholar
• Jenkins J.K., Hardy K.J., McMurray R.W. The pathogenesis of rheumatoid arthritis: A guide to therapy. Amer. J. Med. Sci. 2002; 323(4)171–180
   PubMed Web of Science ®Google Scholar
• Sesin C.A., Bingham C.O. 3rd. Remission in rheumatoid arthritis: Wishful thinking or clinical reality?. Sem. Arthr. Rheumat. 2005; 35(3)185–196
   PubMed Web of Science ®Google Scholar
• Sacerdote P., Massi P., Panerai A.E., Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 2000; 109(2)155–163
   PubMed Web of Science ®Google Scholar
• Derocq J.M., Jbilo O., Bouaboula M., Segui M., Clere C., Casellas P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem. 2000; 275(21)15621–15628
   PubMed Web of Science ®Google Scholar
• Jorda M.A., Verbakel S.E., Valk P.J., Vankan-Berkhoudt Y.V., Maccarrone M., Finazzi-Agro A., Lowenberg B., Delwel R. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood. 2002; 99(8)2786–2793
   PubMed Web of Science ®Google Scholar
• Kishimoto S., Gokoh M., Oka S., Muramatsu M., Kajiwara T., Waku K., Sugiura T. 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem. 2003; 278(27)24469–24475
   PubMed Web of Science ®Google Scholar
• Oka S., Ikeda S., Kishimoto S., Gokoh M., Yanagimoto S., Waku K., Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J. Leuk. Biol. 2004; 76(5)1002–1009
   PubMed Web of Science ®Google Scholar
• Maestroni G.J. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. Feder. Amer. Soc. Exper. Biol. J. 2004; 18(15)1914–1916
   PubMed Web of Science ®Google Scholar
• Wolfe F., Hawley D.J. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J. Rheumatol. 1998; 25(11)2108–2117
   PubMed Web of Science ®Google Scholar
• Molenaar E.T., Voskuyl A.E., Dinant H.J., Bezemer P.D., Boers M., Dijkmans B.A. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthr. Rheum. 2004; 50(1)36–42
   PubMed Web of Science ®Google Scholar
• Mbvundula E.C., Bunning R.A., Rainsford K.D. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 2005; 69(4)635–640
   PubMed Web of Science ®Google Scholar
• Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. Amer. Asso. Pharm. Sci. J. 2005; 7(1)E143–E148
   Google Scholar
• Gokoh M., Kishimoto S., Oka S., Mori M., Waku K., Ishima Y., Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem. J. 2005; 386(Pt 3)583–589
   PubMed Web of Science ®Google Scholar
• McGhee J.R., Kunisawa J., Kiyono H. Gut lymphocyte migration: we are halfway ‘home’. Trends Immunol. 2007; 28(4)150–153
   PubMed Web of Science ®Google Scholar
• Wei S., Kryczek I., Zou W. Regulatory T-cell compartmentalization and trafficking. Blood. 2006; 108(2)426–431
   PubMed Web of Science ®Google Scholar
• Cox K.A., Dunn-Meynell K., Korfmacher W.A., Broske L., Nomeir A.A., Lin C.C., Cayen M.N., Barr W.H. Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discov. Today. 1999; 4(5)232–237
   PubMed Web of Science ®Google Scholar